Teva Pharmaceutical Industries Target of Unusually Large Options Trading (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVAGet Free Report) was the recipient of some unusual options trading activity on Tuesday. Stock investors bought 35,981 call options on the stock. This is an increase of 112% compared to the average daily volume of 16,944 call options.

Institutional Trading of Teva Pharmaceutical Industries

A number of hedge funds have recently bought and sold shares of TEVA. Tobam purchased a new stake in Teva Pharmaceutical Industries during the second quarter valued at $25,000. Money Concepts Capital Corp purchased a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at $25,000. Tower Research Capital LLC TRC increased its position in Teva Pharmaceutical Industries by 1,729.5% during the third quarter. Tower Research Capital LLC TRC now owns 3,787 shares of the company’s stock valued at $39,000 after acquiring an additional 3,580 shares during the last quarter. Spire Wealth Management increased its position in Teva Pharmaceutical Industries by 32.7% during the second quarter. Spire Wealth Management now owns 5,584 shares of the company’s stock valued at $42,000 after acquiring an additional 1,375 shares during the last quarter. Finally, Blue Trust Inc. increased its position in Teva Pharmaceutical Industries by 92.3% during the fourth quarter. Blue Trust Inc. now owns 4,541 shares of the company’s stock valued at $46,000 after acquiring an additional 2,180 shares during the last quarter. Hedge funds and other institutional investors own 43.23% of the company’s stock.

Teva Pharmaceutical Industries Trading Down 0.8 %

TEVA stock opened at $11.73 on Wednesday. Teva Pharmaceutical Industries has a 1-year low of $7.09 and a 1-year high of $12.21. The business has a fifty day moving average price of $10.62 and a 200-day moving average price of $9.74. The company has a debt-to-equity ratio of 2.46, a quick ratio of 0.65 and a current ratio of 1.00.

Teva Pharmaceutical Industries (NYSE:TEVAGet Free Report) last posted its quarterly earnings results on Wednesday, November 8th. The company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.03. Teva Pharmaceutical Industries had a positive return on equity of 29.91% and a negative net margin of 14.46%. The firm had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.73 billion. During the same quarter in the previous year, the business earned $0.56 earnings per share. The company’s revenue was up 8.3% on a year-over-year basis. On average, equities research analysts anticipate that Teva Pharmaceutical Industries will post 2.22 EPS for the current year.

Analysts Set New Price Targets

TEVA has been the subject of a number of research reports. StockNews.com initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Thursday, October 5th. They issued a “buy” rating for the company. Barclays increased their price target on shares of Teva Pharmaceutical Industries from $14.00 to $15.00 and gave the stock an “overweight” rating in a research note on Monday. Jefferies Financial Group raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and increased their price target for the stock from $10.00 to $14.00 in a research note on Tuesday, January 23rd. UBS Group raised shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and increased their price target for the stock from $11.00 to $13.00 in a research note on Monday, November 27th. Finally, Piper Sandler raised Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and boosted their target price for the stock from $8.00 to $12.00 in a report on Wednesday, January 3rd. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $12.86.

Get Our Latest Stock Analysis on TEVA

About Teva Pharmaceutical Industries

(Get Free Report)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.

Read More

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.